If you are considering prostate cancer surgery, you may hear your surgeon talk about nerve-sparing surgery. This technique aims to preserve the delicate nerve bundles that run alongside the prostate and are responsible for erectile function. The goal is to remove the cancer effectively while reducing the risk of long-term side effects that can affect your quality of life.
One of the main challenges in prostate cancer surgery is that these nerves sit extremely close to the prostate gland. In some cases, the cancer may be located near the outer edge of the prostate, making it difficult to know whether preserving the nerves is completely safe. Removing too much tissue can affect functional outcomes, while preserving too much may increase the risk of leaving cancer cells behind.
The NeuroSAFE technique was developed to help surgeons make these decisions with additional information during the operation. It involves a rapid frozen-section analysis of tissue taken from areas close to the nerve bundles, allowing the surgical team to check for cancer at the surgical margin while the procedure is still underway. If cancer is detected near the margin, the surgeon can modify the surgical plan immediately, helping to balance cancer control with the preservation of important functions wherever possible.
What Does NeuroSAFE Mean?
NeuroSAFE stands for neurovascular structure-adjacent frozen-section examination. Although the name sounds highly technical, the concept is relatively straightforward. It is a technique used during prostate cancer surgery to help your surgeon decide whether the nerves alongside the prostate can be safely preserved.
During the operation, your surgeon removes the prostate and sends selected tissue samples from areas close to the nerve bundles to a specialist pathologist. These samples are rapidly frozen and examined under a microscope while the procedure is still taking place. This allows your surgical team to receive immediate information about whether cancer cells are present at the edge of the removed tissue.
Having this information available in real time can help guide important decisions during surgery. If the margins are clear of cancer, your surgeon may be able to continue with a nerve-sparing approach with greater confidence. If cancer is found near the margin, additional tissue can be removed to reduce the risk of leaving cancer behind while still aiming to preserve function whenever it is safe to do so.
Why Nerve-Sparing Matters in Prostate Surgery
The nerve bundles that run alongside the prostate play an important role in erectile function. If you are having prostate cancer surgery, preserving these nerves where it is safe to do so may improve your chances of recovering erections after treatment. This is one reason why nerve-sparing techniques are often considered during surgical planning.
Nerve-sparing surgery may also contribute to better functional recovery for some men after their operation. Preserving these structures can help support quality of life, particularly when sexual function is an important concern for you. However, your surgeon must never preserve the nerves at the expense of removing the cancer safely and completely.
This creates a careful balance during prostate cancer surgery. Your surgeon needs to achieve the best possible cancer control while preserving function whenever it is appropriate. The NeuroSAFE technique helps support these decisions by providing additional information during the operation, allowing treatment to be tailored more precisely to your situation.
Why the Decision Is Difficult Without NeuroSAFE
Before and during surgery, your surgeon must judge how close the cancer may be to the edge of the prostate. This assessment is based on MRI scans, biopsy results, PSA levels, examination findings, and surgical experience. These tools are helpful, but they cannot provide complete certainty.
Even with careful planning, it can be difficult to know exactly where microscopic cancer cells extend. Imaging and biopsy results offer valuable guidance, but they cannot show every cancer cell at the surface of the prostate. This can make surgical decision-making more challenging.
Without NeuroSAFE, your surgeon may choose a wider excision to reduce the risk of leaving cancer behind. While this can support cancer control, it may reduce the opportunity to preserve the nearby nerves. For you, this could affect the chances of maintaining erectile function after surgery.
How NeuroSAFE Works During Surgery
After the prostate has been removed, tissue from areas close to the nerve bundles is carefully prepared for examination. These samples are rapidly frozen, sliced into thin sections, and stained for analysis. This process takes place while the operation is still ongoing.
A specialist pathologist then examines the tissue under a microscope. The aim is to check whether cancer cells are present at the surgical edge near the nerve-sparing area. This assessment is known as frozen-section analysis.
If cancer cells are found at the margin, your surgeon can respond immediately. Additional tissue can be removed from the affected side while you are still under anaesthetic. This real-time feedback is what makes the NeuroSAFE technique unique and valuable.
What Is a Surgical Margin?
A surgical margin refers to the edge of the tissue removed during an operation. If you are undergoing prostate cancer surgery, your surgeon will aim to remove the cancer with a margin of healthy tissue around it. When cancer cells are found at the cut edge of the removed prostate on pathology examination, this is known as a positive surgical margin.
A positive surgical margin does not necessarily mean that the cancer will return. However, it can be associated with a higher risk of recurrence and may mean you need closer monitoring or additional treatment after surgery. This is one reason why achieving clear margins is such an important goal.
NeuroSAFE focuses on the surgical margin closest to the neurovascular bundles. This is the area where your surgeon must balance the desire to preserve the nerves with the need to remove the cancer completely. The technique provides additional information that can help guide decisions affecting both your cancer treatment and functional outcomes.
What Are Neurovascular Bundles?
The neurovascular bundles are structures that run alongside the prostate. They contain nerves and blood vessels that play an important role in erectile function. If you are considering prostate cancer surgery, you may hear your surgeon refer to these bundles when discussing nerve-sparing options.
These structures lie just outside the capsule of the prostate. Because of their close proximity, they can be affected during a radical prostatectomy. Protecting them can be beneficial, but it is not always possible in every case.
If the cancer is a safe distance from the neurovascular bundles, your surgeon may be able to preserve them during the operation. However, if cancer is very close to these structures, removing additional tissue may provide better cancer control. The decision will depend on your individual cancer characteristics and surgical findings.
What Was the Purpose of the NeuroSAFE Study?
The purpose of the NeuroSAFE study was to find out whether surgeons could preserve more nerves without increasing the risk of leaving cancer behind. If you are considering prostate cancer surgery, this is an important question because both cancer control and functional recovery matter. Researchers wanted to see whether real-time pathology assessment could help achieve a better balance between these two goals.
Several studies have evaluated NeuroSAFE in clinical practice over the years. More recently, researchers have compared NeuroSAFE-guided surgery with standard robot-assisted prostatectomy in randomised trials. These studies provide stronger evidence about how the technique may affect outcomes for patients like you.
The key question behind the research is simple but important. Can your surgeon safely preserve more nerves when immediate information is available during the operation? By answering this question, researchers hope to determine whether NeuroSAFE can improve functional outcomes without compromising cancer control.
What Did Earlier NeuroSAFE Research Suggest?
Earlier observational studies suggested that NeuroSAFE could increase the use of nerve-sparing surgery. This meant that more men were able to have one or both neurovascular bundles preserved during their operation. If you are concerned about functional recovery after surgery, these findings are particularly relevant.
Researchers also found that NeuroSAFE did not appear to compromise important cancer outcomes when used in experienced centres. A 2022 validation study reported higher rates of unilateral and bilateral nerve-sparing surgery without negative effects on surgical margin status or biochemical recurrence. These results suggested that surgeons could preserve nerves more often while maintaining cancer control.
However, observational studies have important limitations. Although they can provide useful insights, they do not compare patients as directly as randomised trials. For you as a patient, evidence from randomised research generally provides greater confidence when assessing the benefits and safety of a treatment approach.
What Did the Recent Randomised NeuroSAFE Trial Show?
A recent randomised trial compared NeuroSAFE-guided robotic prostate surgery with standard robotic prostate surgery. The researchers wanted to see whether having real-time pathology information during the operation could improve outcomes for patients. This gave a clearer picture of how NeuroSAFE performs in practice.
The study found that men who underwent NeuroSAFE-guided surgery reported better erectile function 12 months after treatment. It also showed improvements in short-term urinary continence. If you are concerned about recovery after surgery, these findings may be reassuring.
The benefits appeared particularly relevant for men who may not otherwise have been considered suitable for bilateral nerve-sparing surgery. By providing immediate feedback during the operation, NeuroSAFE can help your surgeon make more informed decisions. This may allow you to preserve function while still maintaining a strong focus on cancer control.
Key NeuroSAFE Outcomes and Patient Considerations
| Aspect | Description | Findings / Benefits | Considerations / Limitations |
| Technique | Rapid frozen-section pathology during prostatectomy | Guides intraoperative nerve-sparing decisions | Requires trained pathologists and coordinated workflow |
| Purpose | Assess tissue adjacent to neurovascular bundles in real time | Supports preservation of erectile function while maintaining cancer control | Does not guarantee nerve preservation or full erectile recovery |
| Erectile Function | Impact on recovery | NeuroSAFE PROOF trial: 12 months post-op, 39% had no/mild ED vs 23% with standard surgery | Benefits mostly observed in men with good pre-op function; recovery varies by age and health |
| Urinary Continence | Short-term recovery | Improved continence at 3 months in NeuroSAFE group | Difference not significant at 6 months; overall recovery influenced by multiple factors |
| Nerve-Sparing | Bilateral & unilateral | Increased rates of bilateral nerve-sparing; unilateral sparing guided safely | Dependent on cancer location and intraoperative findings |
| Cancer Control | Oncological safety | Early data show similar positive margin rates and biochemical recurrence | Long-term randomized follow-up ongoing |
| Surgical Time | Operative considerations | Adds time for tissue processing and pathology review | Extra duration varies by centre; workflow efficiency important |
| Patient Suitability | Who benefits most | Men with good pre-op erectile function; borderline cases for nerve preservation | Not suitable for all patients; pre-existing ED or extensive cancer may limit benefit |
| Integration with Pre-op Assessment | MRI, PSA, biopsy | Complements standard pre-operative imaging and biopsy | Does not replace MRI or biopsy; used alongside other diagnostics |
Evidence Note: NeuroSAFE PROOF Trial Results
The NeuroSAFE PROOF trial was a multicentre, patient-blinded, randomised phase 3 trial conducted in five UK NHS hospitals. Among 381 men who underwent surgery, erectile function at 12 months was better after NeuroSAFE-guided robotic prostatectomy than after standard robotic surgery. The average IIEF-5 erectile-function score was 12.7 in the NeuroSAFE group compared with 9.7 in the standard-surgery group.
At 12 months, around 39% of men receiving NeuroSAFE reported no or mild erectile dysfunction, compared with approximately 23% after standard surgery. Severe erectile dysfunction was reported by 38% and 56% respectively. NeuroSAFE also increased the proportion of men receiving bilateral nerve-sparing surgery. These results are most relevant to men who had good erectile function before surgery, because that was an important eligibility requirement in the trial.
Clinical Nuance: Who Was Studied?
The NeuroSAFE PROOF results should not be applied equally to every patient undergoing prostatectomy. Participants had good erectile function before surgery and were considered suitable for robotic radical prostatectomy. Your likely benefit may be different if you already have erectile dysfunction, significant vascular disease, previous pelvic treatment or cancer that clearly requires wide removal around both nerve bundles.
How NeuroSAFE May Improve Erectile Function Recovery
Erectile function recovery after prostate cancer surgery depends on several factors. These include your age, erectile function before surgery, general health, smoking status, and whether one or both nerve bundles can be preserved. Because every patient is different, recovery can vary considerably from one person to another.
NeuroSAFE may support recovery by helping your surgeon make more informed decisions about whether nerve preservation is appropriate. If the tissue margin next to a nerve bundle is clear of cancer, it may be possible to preserve that nerve safely. This can be particularly helpful when the original surgical plan would otherwise have been more cautious.
It is important to understand that NeuroSAFE does not guarantee the return of erections after surgery. Even when nerves are preserved, healing and recovery can take time. For you, the main benefit of NeuroSAFE is that it supports more informed surgical decision-making while maintaining a focus on cancer control.
Does NeuroSAFE Guarantee Nerve Preservation?
No, NeuroSAFE does not guarantee that the nerves will be preserved during surgery. It provides your surgeon with additional information while the operation is taking place, but cancer control remains the highest priority. The final decision will always depend on what is safest from an oncological perspective.
If frozen-section analysis shows cancer at the margin near a nerve bundle, your surgeon may need to remove additional tissue from that area. In some cases, this can mean sacrificing part or all of the nerve tissue to reduce the risk of leaving cancer behind. The aim is to achieve the best possible balance between preserving function and treating the cancer effectively.
For this reason, NeuroSAFE should not be viewed as a promise of full nerve-sparing surgery. Instead, it is a tool that helps your surgeon make more precise decisions during the operation. For you, its value lies in providing greater confidence that nerve preservation is being pursued only when it is safe to do so.
How NeuroSAFE Supports Cancer Control
One of the main advantages of NeuroSAFE is that it allows your surgeon to assess nerve-adjacent surgical margins during the operation. If cancer cells are found at the margin, additional tissue can be removed immediately. This helps ensure that important decisions are made while the procedure is still underway.
This approach differs from relying solely on the final pathology report after surgery. Once the operation has finished, there is no opportunity to adjust the extent of tissue removal during the same procedure. Real-time feedback gives your surgeon valuable information at the point when it can have the greatest impact.
Current evidence is reassuring about cancer control, but it should be interpreted carefully. Observational studies and systematic reviews report higher nerve-sparing rates, without clear evidence of worse biochemical recurrence outcomes, and some studies have reported lower positive-margin rates. The NeuroSAFE PROOF trial also reported broadly similar early oncological outcomes between groups. However, prostate cancer can recur many years after surgery, so longer randomised follow-up is still needed before equivalent long-term cancer control can be confirmed.
What Is Frozen-Section Analysis?
Frozen-section analysis is a rapid pathology technique used during surgery. Tissue samples are frozen, cut into very thin sections, stained, and examined under a microscope while the operation is still taking place. This allows important information to be provided without delaying the procedure.
It is different from the final pathology report, which is completed after surgery using more detailed and time-intensive processing methods. While the final report provides a comprehensive assessment, frozen-section analysis is designed to answer a specific question quickly. This helps your surgeon make decisions during the operation rather than afterwards.
In the NeuroSAFE technique, the key question is whether cancer is present at the surgical margin next to the nerve bundles. If cancer cells are identified, your surgeon can consider removing additional tissue from that area. For you, this real-time information may help support both effective cancer treatment and appropriate nerve preservation.
Why the Pathologist Is Essential
The NeuroSAFE technique relies on close collaboration between the surgeon and the pathologist. Your surgeon must remove and label the tissue correctly, while the pathologist must examine the relevant margins accurately. Both roles are essential for the process to work effectively.
NeuroSAFE is not simply a surgical technique. It also involves a specialised pathology workflow that requires experience, precise timing, and clear communication between members of the clinical team. Each step must be carried out carefully to provide reliable results during the operation.
For this reason, a centre offering NeuroSAFE needs the right expertise and systems in place. Without dedicated pathology support, the technique cannot be performed as intended. If you are considering NeuroSAFE-guided surgery, it is worth choosing a centre with experience in both the surgical and pathology aspects of the procedure.
Why NeuroSAFE Requires Planning
NeuroSAFE cannot simply be added to a prostate cancer operation at the last minute. It requires careful planning before surgery, along with coordination between the surgical and pathology teams. If you are having NeuroSAFE-guided surgery, several preparations need to be in place before the procedure begins.
The team must decide which areas of the prostate will be assessed and how the findings may influence the operation. Your surgeon also needs to consider how the results will guide nerve-sparing decisions during surgery. The entire process must run efficiently so that the procedure is not unnecessarily prolonged.
This is one reason why NeuroSAFE is most commonly offered in specialist centres. It relies on a coordinated pathway involving multiple professionals rather than a single technical step. For you, this means the technique requires both expertise and organisation to be performed effectively.
Does NeuroSAFE Make Surgery Longer?
NeuroSAFE can add some time to a prostate cancer operation because tissue samples need to be processed and examined while surgery is still underway. The amount of extra time varies between centres and depends on the pathology workflow and complexity of the case. In most cases, this additional step is carefully integrated into the procedure.
For many patients, the extra time may be worthwhile if it helps support safer nerve preservation. By providing information during the operation, NeuroSAFE can help your surgeon make more informed decisions about the extent of tissue removal. This potential benefit is one reason why the technique has gained increasing interest.
Before surgery, your surgeon should explain whether NeuroSAFE is suitable for your particular situation. The potential advantages need to be considered alongside your cancer characteristics, treatment goals, and recovery priorities. This helps ensure that the approach chosen is appropriate for you.
Who May Benefit From NeuroSAFE?
NeuroSAFE may be particularly useful when it is unclear whether nerve-sparing surgery can be performed safely. This situation can arise when cancer appears close to one side of the prostate, making the decision more challenging. In these cases, your surgeon may use NeuroSAFE to gain additional information before deciding whether to preserve a nerve bundle.
If you have good erectile function before surgery, preserving the nerves may be an important consideration. Techniques such as NeuroSAFE may help improve the chances of functional recovery by supporting more confident nerve-sparing decisions. However, cancer control must always remain the primary objective.
Not every patient will benefit from NeuroSAFE to the same extent. If the cancer is clearly well away from the nerves, or clearly too close for safe nerve preservation, the additional information may have less impact on the surgical plan. Your surgeon can explain whether NeuroSAFE is likely to add value in your particular situation.
NeuroSAFE and Bilateral Nerve-Sparing
Bilateral nerve-sparing means preserving both neurovascular bundles during prostate cancer surgery. When this can be done safely, it may offer the best chance of recovering erectile function after treatment. For many men, this is an important goal of nerve-sparing surgery.
NeuroSAFE may increase the number of men who can undergo bilateral nerve-sparing. By checking nerve-adjacent margins during the operation, it gives your surgeon more confidence when deciding whether both nerve bundles can be preserved. If you are hoping to maximise functional recovery, this additional information may be valuable.
However, bilateral nerve-sparing is not always possible. If cancer is found at the margin, your surgeon may need to remove additional tissue to achieve safe cancer control. For you, the priority should always be complete cancer removal, even when nerve preservation is desirable.
NeuroSAFE and Unilateral Nerve-Sparing
Unilateral nerve-sparing means that one nerve bundle is preserved while the other side is removed more widely. This approach may be used when cancer appears closer to one side of the prostate. It allows your surgeon to balance nerve preservation with effective cancer treatment.
NeuroSAFE can help assess whether the side selected for nerve-sparing can be preserved safely. During the operation, the tissue margin next to the nerve bundle is examined using frozen-section analysis. If the margin is clear, your surgeon may continue with the planned nerve-sparing approach.
However, the surgical plan can change if cancer is found near the preserved side. Your surgeon may decide to remove additional tissue to reduce the risk of leaving cancer behind. While this may limit nerve preservation, it can improve cancer safety and treatment outcomes.
What Happens If NeuroSAFE Finds Cancer at the Margin?
If frozen-section analysis shows cancer at the nerve-adjacent margin, your surgeon can remove additional tissue from that area during the operation. This step is sometimes referred to as a secondary resection. It allows action to be taken immediately rather than waiting until after surgery.
The goal is to improve the surgical outcome by reducing the risk of leaving cancer cells behind. This real-time response is one of the key advantages of the NeuroSAFE technique. It gives your surgeon important information at a stage when treatment decisions can still be adjusted.
However, removing additional tissue may affect nerve preservation on the affected side. If you are considering NeuroSAFE-guided surgery, your surgeon should discuss this possibility with you beforehand. This helps you understand the balance between preserving function and achieving the safest possible cancer control.
What Happens If NeuroSAFE Is Clear?
If the frozen-section analysis is clear, your surgeon may feel more confident about preserving the nerve bundle on that side. This can support a more function-preserving operation when cancer safety allows. For you, this may increase the opportunity for nerve preservation without compromising the surgical plan.
A clear NeuroSAFE result is reassuring for the specific area that has been examined. However, it does not replace the final pathology report, which provides a more detailed assessment of the removed prostate. Your tissue will still undergo comprehensive analysis after the operation.
It is helpful to view NeuroSAFE as a guide that supports decision-making during surgery. The technique provides valuable information while the procedure is taking place, but it is not the final word on the cancer. Your complete pathology results will still determine the final assessment after surgery.
Does NeuroSAFE Replace MRI or Biopsy?
No, NeuroSAFE does not replace MRI scans, biopsies, PSA testing, or other pre-operative assessments. These investigations remain essential for diagnosing prostate cancer and planning treatment. If you are considering surgery, your care team will still rely on these tests to understand the extent of the disease.
MRI scans and biopsy results help your surgeon assess whether surgery is appropriate and what type of nerve-sparing approach may be possible. They provide important information before the operation begins. NeuroSAFE adds another layer of information by assessing selected margins during surgery itself.
The best outcomes come from combining thorough pre-operative assessment with careful decision-making in the operating theatre. NeuroSAFE supports this process, but it is only one part of the overall treatment pathway. For you, it should be viewed as an additional tool rather than a replacement for established investigations.
Why Pre-Surgery Erectile Function Still Matters
Your erectile function before surgery is one of the strongest predictors of recovery afterwards. If you had good erections before treatment, preserving the nerves may offer a greater opportunity for functional recovery. This is why your pre-operative sexual function is an important part of surgical planning.
If you already had erectile dysfunction before surgery, NeuroSAFE may still help guide nerve-sparing decisions. However, the potential improvement in erectile function after treatment may be more limited. This does not mean that support or treatment options will not be available during recovery.
Before surgery, your surgeon should discuss your erectile function and ask about any existing difficulties. Being open about these issues helps create more realistic expectations and a more personalised recovery plan. For you, this can make it easier to understand the likely outcomes after treatment.
NeuroSAFE and Urinary Continence
NeuroSAFE is usually discussed for nerve preservation and erectile function after prostate cancer surgery, but it can also relate to urinary control. Understanding both outcomes helps you have informed discussions with your surgeon before surgery.
- Short-Term Benefits: A recent randomised NeuroSAFE trial reported improvements in short-term urinary continence alongside better erectile function outcomes.
- Long-Term Impact: While early results are promising, more research is needed to understand the long-term effects on continence recovery.
- Factors Affecting Recovery: Age, pre-surgery urinary function, pelvic floor strength, anatomy, surgical approach, and healing all influence urinary control after surgery.
- Setting Realistic Expectations: Knowing what to expect helps you prepare for the recovery process and supports a smoother post-operative experience.
Overall, NeuroSAFE may offer short-term benefits for urinary continence in addition to erectile function, but outcomes vary for each patient. Discussing your personal situation with your surgeon is important for realistic planning.
What Are the Limits of the Evidence?
Although research on NeuroSAFE has grown, it is important to understand that the evidence is still developing. Studies vary in their design, patient groups, surgical expertise, pathology processes, and ways of measuring outcomes. These differences can make comparisons between studies more difficult.
A systematic review found promising results for NeuroSAFE but also highlighted limitations in the available evidence. More recent randomised trial data has helped provide stronger information about its potential benefits. However, ongoing research will continue to improve our understanding of the technique.
This does not mean NeuroSAFE lacks value. It means you should receive balanced information about both the potential benefits and limitations. Your surgeon can help you understand whether the technique is suitable for your individual diagnosis and treatment goals.
Why Surgical Experience Still Matters
NeuroSAFE is a technique that supports your surgeon, but it does not replace surgical expertise. The surgeon still needs to perform careful dissection, understand your individual cancer situation, and respond appropriately to the pathology results during the operation.
Robotic technology and NeuroSAFE are valuable tools, but their benefits depend on how they are used. Your anatomy, cancer characteristics, and the experience of the surgical team all play an important role in the final outcome.
If you are considering NeuroSAFE-guided surgery, it is worth asking how the team uses this technique in practice. The availability of NeuroSAFE is important, but experience with the complete surgical pathway is equally valuable. A well-coordinated team can help you receive care that is tailored to your needs.
Choosing Specialist NeuroSAFE Care
NeuroSAFE requires coordination between robotic surgery, pathology, anaesthesia, and post-operative care. If you are considering this approach, it is important to choose a team that understands the technique and can explain whether it is suitable for your situation.
A specialist consultation should look at your MRI results, biopsy findings, PSA level, and baseline function before planning nerve preservation. Your surgeon should explain both the potential benefits and the limitations of NeuroSAFE. This helps you make a more informed decision about your treatment.
You should also ask how your recovery will be supported after surgery, including erectile function and urinary continence. NeuroSAFE can help guide surgical decisions, but your overall recovery depends on many factors. A complete care pathway is important for achieving the best possible outcome.
UK Guidance Note
NICE does not currently recommend routine NeuroSAFE use during radical prostatectomy. However, NICE recommends that men considering radical treatment receive objective information about treatment benefits, urinary effects, sexual-function changes and quality-of-life outcomes. NICE also recommends access to specialist erectile-dysfunction and continence services after treatment when needed.
For you, this means a NeuroSAFE consultation should cover more than the surgical technique itself. You should also receive realistic information about erectile recovery, urinary continence, final pathology, PSA follow-up and rehabilitation after surgery.
What NeuroSAFE Means for Prostate Cancer Surgery
The importance of NeuroSAFE is that it helps your surgeon make more informed decisions during prostate cancer surgery. It allows nerves to be preserved when it is safe to do so and helps identify when additional tissue may need to be removed. This approach aims to balance cancer control with the preservation of important functions.
Traditionally, nerve-sparing decisions relied mainly on information available before surgery. NeuroSAFE adds real-time pathology information during the operation, which can be especially valuable when the cancer is close to the nerve bundles. For you, this may provide a more personalised approach to surgical planning.
However, NeuroSAFE does not remove every risk or guarantee a perfect recovery. Its main benefit is helping your surgical team balance two important goals: removing the cancer safely and protecting your quality of life wherever possible. Your individual outcome will still depend on your cancer, treatment, and recovery factors.
Myth vs Fact
| Myth | Fact |
| NeuroSAFE guarantees that both nerves will be preserved. | Cancer at the margin may require additional tissue or nerve removal. |
| NeuroSAFE guarantees normal erections after surgery. | Recovery also depends on age, baseline function, vascular health and healing. |
| A clear frozen section means the final pathology will always be clear. | Frozen-section analysis guides surgery, but full permanent-section pathology is still required. |
| NeuroSAFE has proven superior long-term cancer survival outcomes. | Early cancer-control findings are reassuring, but long-term randomised follow-up is still developing. |
| NeuroSAFE replaces MRI and biopsy. | MRI, biopsy and PSA remain essential before surgery. |
| NeuroSAFE always improves long-term continence. | The randomised trial found better continence at 3 months, but not a significant difference at 6 months. |
| Every prostatectomy centre can offer NeuroSAFE. | It requires trained pathologists, rapid processing and coordinated specialist facilities. |
Key Takeaways
- NeuroSAFE uses rapid frozen-section pathology during radical prostatectomy.
- It examines tissue close to the neurovascular bundles while surgery is still taking place.
- If cancer is found at the margin, additional tissue can be removed during the same operation.
- The NeuroSAFE PROOF trial showed better erectile-function outcomes at 12 months among selected men with good erectile function before surgery.
- NeuroSAFE increased the likelihood of bilateral nerve-sparing in the randomised trial.
- Continence scores improved at 3 months, but the difference was not significant at 6 months.
- NeuroSAFE does not guarantee nerve preservation, erections or continence.
- Early cancer-control results are reassuring, but longer randomised follow-up remains important.
- The technique requires an experienced surgeon, specialist pathologist and coordinated theatre workflow.
FAQs:
1. What is the NeuroSAFE technique in prostate cancer surgery?
NeuroSAFE is a technique used during prostate cancer surgery to assess tissue close to the nerve bundles while the operation is still taking place. A pathologist examines the tissue using rapid frozen-section analysis and provides immediate feedback to the surgeon. This information can help guide nerve-sparing decisions in real time.
2. How does NeuroSAFE help preserve erectile function?
NeuroSAFE can help surgeons identify when it is safe to preserve the nerves responsible for erectile function. By confirming whether cancer is present near the surgical margin, it may allow more confident nerve-sparing in suitable patients. This may improve the opportunity for erectile function recovery after surgery, although outcomes vary between individuals.
3. Does NeuroSAFE guarantee erections after prostate surgery?
No, NeuroSAFE does not guarantee erectile function recovery. Age, pre-operative erectile function, overall health and the extent of nerve preservation all influence recovery. NeuroSAFE is designed to improve surgical decision-making rather than guarantee a specific outcome.
4. Is NeuroSAFE safe from a cancer-control perspective?
Research suggests that NeuroSAFE can support nerve-sparing while maintaining good cancer-control outcomes in appropriately selected patients. If cancer is detected at the margin during surgery, additional tissue can be removed immediately. This helps balance the goals of preserving function and removing the cancer safely.
5. Who is most likely to benefit from NeuroSAFE?
NeuroSAFE may be most useful when it is unclear whether nerve-sparing can be performed safely. This often applies when cancer appears close to the edge of the prostate on scans or biopsy results. The technique provides additional information that can help guide surgical decisions during the operation.
6. Does NeuroSAFE add time to the operation?
Yes, NeuroSAFE can increase the length of the procedure because tissue samples must be processed and examined during surgery. The amount of extra time varies depending on the hospital and pathology workflow. Your surgeon can explain how NeuroSAFE may affect the duration of your operation.
7. Can NeuroSAFE be used with robotic prostate surgery?
Yes, NeuroSAFE is commonly performed during robot-assisted radical prostatectomy. The technique works alongside robotic surgery by providing real-time pathology information while the operation is underway. This can help surgeons make more informed nerve-sparing decisions.
8. What happens if NeuroSAFE detects cancer at the surgical margin?
If cancer is found at the nerve-adjacent margin, the surgeon may remove additional tissue from that area during the same operation. This is done to reduce the risk of leaving cancer cells behind. In some cases, it may mean preserving less nerve tissue on the affected side.
9. Does NeuroSAFE replace MRI scans and prostate biopsies?
No, NeuroSAFE does not replace MRI scans, PSA testing or prostate biopsies. These investigations remain essential for diagnosing prostate cancer and planning treatment. NeuroSAFE provides additional information during surgery to support decision-making.
10. Is NeuroSAFE available for all prostate cancer patients?
Not all patients will require or benefit from NeuroSAFE. Its suitability depends on factors such as cancer location, MRI findings, biopsy results and the planned surgical approach. Your surgeon can explain whether NeuroSAFE is appropriate for your individual situation.
Final Thoughts: Why NeuroSAFE Matters for Modern Prostate Cancer Surgery
NeuroSAFE has influenced how some specialist teams approach nerve-sparing prostate cancer surgery. By providing real-time information about surgical margins during the operation, it can help surgeons make more informed decisions about when nerves can be safely preserved and when additional tissue should be removed. This approach aims to balance two important goals: achieving effective cancer control while maximising the chance of preserving important functions and supporting recovery after surgery.
Although NeuroSAFE is not suitable for every patient and cannot guarantee specific outcomes, the growing evidence suggests that it can offer meaningful benefits in carefully selected cases. If you are considering prostate cancer surgery, it is important to discuss all available options with an experienced specialist. If you would like to find out whether NeuroSAFE prostate surgery in London could be suitable for you, speaking with an experienced prostate cancer surgeon can help you understand how the technique may fit into your treatment plan and what outcomes you may realistically expect.
References:
- National Institute for Health and Care Excellence (NICE) (2019, last updated 2021; reviewed 2025) Prostate cancer: diagnosis and management. NICE guideline NG131. Available at: nice.org.uk/guidance/ng131
- NHS (no date) Treatment for prostate cancer. Available at: nhs.uk/conditions/prostate-cancer/treatment
- Prostate Cancer UK (no date) Surgery: radical prostatectomy. Available at: prostatecanceruk.org/prostate-information-and-support/treatments/surgery
- Cancer Research UK (no date) Problems after prostate cancer surgery. Available at: cancerresearchuk.org/about-cancer/…/problems-after-prostate-surgery
- Dinneen, E. et al. (2025) ‘NeuroSAFE-guided versus standard robot-assisted radical prostatectomy: the NeuroSAFE PROOF trial’, The Lancet Oncology, 26(4), pp.447–458. Available at: pubmed.ncbi.nlm.nih.gov/40147459
- Kroon, L.J. et al. (2025) ‘NeuroSAFE during radical prostatectomy: systematic review and meta-analysis’, European Urology Oncology. Available at: pubmed.ncbi.nlm.nih.gov/39730246
- van der Slot, M.A. et al. (2022) ‘NeuroSAFE increases nerve-sparing without affecting oncological outcomes’, BJU International, 130(5), pp.628–636. Available at: pubmed.ncbi.nlm.nih.gov/35536200
- Noël, J. et al. (2022) ‘NeuroSAFE robot-assisted radical prostatectomy: outcomes from 500 consecutive UK cases’, Journal of Robotic Surgery, 16, pp.951–956. Available at: pubmed.ncbi.nlm.nih.gov/34716876